You're correct about it being an excellent presentation. In discussing the long term survivors from as far back as the Phase 1 I believe the Drs. discussed benefits I've not heard discussed before, even if we knew they existed. I also liked the fact that they discussed being able to get the vaccine under compassionate use in the U.K.
It's sad that commercial production appears to be what's preventing making the vaccine available to more people sooner. I suspect that if compassionate use were available here in the U.S. as it is in the U.K., far more people would be willing to pay for it provided they didn't have to move to get it.
For now, nothing should be of higher priority than gaining approval of the Flaskworks unit. I would still suspect that the list price for the vaccine will be nearly what's being paid in the U.K. for compassionate use, the huge difference will be that insurance will cover the burden, not the individual patient. I'm not certain that if a patient here filed suit against their insurance here they couldn't force at least partial payment for the drug from the U.K. given what the Drs. had to say about it.
Gary
Bullish
Market Data 
Markets 
AI
